Data on the detection of clinically significant prostate cancer by magnetic resonance imaging (MRI)-guided targeted and systematic biopsy
M Klingebiel,
C Arsov,
T Ullrich,
M Quentin,
R Al-Monajjed,
D Mally,
LM Sawicki,
A Hiester,
I Esposito,
P Albers,
G Antoch,
L Schimmöller
Affiliations
M Klingebiel
University Dusseldorf, Medical Faculty, Department of Diagnostic and Interventional Radiology, D-40225 Dusseldorf, Germany
C Arsov
University Dusseldorf, Medical Faculty, Department of Urology, D-40225 Dusseldorf, Germany
T Ullrich
University Dusseldorf, Medical Faculty, Department of Diagnostic and Interventional Radiology, D-40225 Dusseldorf, Germany
M Quentin
University Dusseldorf, Medical Faculty, Department of Diagnostic and Interventional Radiology, D-40225 Dusseldorf, Germany
R Al-Monajjed
University Dusseldorf, Medical Faculty, Department of Urology, D-40225 Dusseldorf, Germany
D Mally
University Dusseldorf, Medical Faculty, Department of Urology, D-40225 Dusseldorf, Germany
LM Sawicki
University Dusseldorf, Medical Faculty, Department of Diagnostic and Interventional Radiology, D-40225 Dusseldorf, Germany
A Hiester
University Dusseldorf, Medical Faculty, Department of Urology, D-40225 Dusseldorf, Germany
I Esposito
University Dusseldorf, Medical Faculty, Department of Pathology, D-40225 Dusseldorf, Germany
P Albers
University Dusseldorf, Medical Faculty, Department of Urology, D-40225 Dusseldorf, Germany
G Antoch
University Dusseldorf, Medical Faculty, Department of Diagnostic and Interventional Radiology, D-40225 Dusseldorf, Germany
L Schimmöller
University Dusseldorf, Medical Faculty, Department of Diagnostic and Interventional Radiology, D-40225 Dusseldorf, Germany; Corresponding author at: University Dusseldorf, Medical Faculty Duesseldorf, Germany.
This is a data article from the original publication “Reasons for missing clinically significant prostate cancer by targeted magnetic resonance imaging/ultrasound fusion-guided biopsy” [1]. From January 2014 to April 2019 a sample collective of 785 patients with 3T multiparametric magnetic resonance imaging (mp-MRI) of the prostate and subsequent combined systematic biopsy (SB) and magnetic resonance imaging/ultrasound (US) fusion-guided biopsy (TB) was retrospectively analyzed. Prostate cancer (PCa) detection by TB and/or additional SB was analyzed.
